Is Nephro Care overvalued or undervalued?

As of 4 September 2025, the valuation grade for Nephro Care has moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios. The PE ratio stands at 76.54, while the EV to EBITDA ratio is 43.95, indicating a premium compared to its peers. The PEG ratio is notably at 0.00, which suggests a lack of growth expectations priced into the stock.
In comparison to its peers, Nephro Care's valuation appears high; for instance, Apollo Hospitals has a PE ratio of 72.11 and an EV to EBITDA of 37.06, which are significantly lower than Nephro Care's metrics. Additionally, Narayana Hrudaya, also categorized as expensive, has a PE ratio of 47.43 and an EV to EBITDA of 29.24. Despite a recent positive stock return of 21.58% over the past month, the overall trend shows a decline of 37.64% over the past year, contrasting with the Sensex's slight decline of 1.84% in the same period, reinforcing the notion that Nephro Care is currently overvalued.